KRRO news

Preclinical data shows KRRO-111 achieves over 95% SERPINA1 editing, restoring functional lung protein and reducing toxic liver buildup, potentially initiating regulatory submissions in the first half of 2027.

The company announced dosing of healthy volunteers in its ANCHOR trial for KRRO-121, a potential treatment for urea cycle disorders, with patient dosing expected to begin in 2027.

Korro Bio advanced KRRO-111, a GalNAc-conjugated oligonucleotide, as a development candidate for alpha-1 antitrypsin deficiency, demonstrating >90% editing of SERPINA1 transcript in preclinical mouse models. The selection expands the company's pipeline alongside KRRO-121 and positions the therapy as…